This work opens the door for new targeted development of novel drugs that target cortical FKBP51, such as SAFiT2 [41], with the potential to treat cognitive deficits, which are the most debilitating but untreated symptoms of psychiatric disorders, via BDNF-mediated synaptic plasticity. Here, BDNF is linked to Cognitive impairment.